Challenges and issues in managing hepatitis C

Anita Maghlaoui1

  • 1Chelsea and Westminster Hospital Foundation Trust, London.

Nursing Times
|August 31, 2012
PubMed

Insights

Hepatitis C virus (HCV) is a global bloodborne infection, with injecting drug users at high risk in industrialised nations. This article reviews HCV epidemiology, diagnosis, treatment strategies, and provides guidance for nurses.

Area of Science:

  • Hepatology
  • Infectious Diseases
  • Public Health

Background:

  • Hepatitis C virus (HCV) infection represents the most prevalent chronic bloodborne infection worldwide.
  • Injecting drug users (IDUs) are disproportionately affected and represent a hard-to-reach population for interventions in the UK and other industrialised countries.

Purpose of the Study:

  • To discuss the epidemiology, diagnosis, and current treatment strategies for HCV.
  • To provide essential information and advice for general nurses managing HCV patients.

Main Methods:

  • Literature review of HCV epidemiology, diagnostic methods, and therapeutic advancements.
  • Synthesis of current clinical guidelines and public health recommendations.
  • Exploration of challenges in reaching and treating at-risk populations like IDUs.

Main Results:

  • HCV remains a significant global health concern, particularly among IDUs.
  • Advances in treatment offer higher cure rates and improved patient outcomes.
  • Targeted outreach and integrated care models are crucial for effective HCV management in at-risk groups.

Conclusions:

  • Comprehensive understanding of HCV epidemiology and diagnostics is vital for effective control.
  • New treatment strategies are transforming HCV management, emphasizing the need for updated nursing knowledge.
  • Nurses play a critical role in HCV prevention, diagnosis, treatment adherence, and harm reduction, especially for hard-to-reach populations.

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...